Daily Archives: March 21, 2020

Diligent Robotics Announces $10M Series A Funding

Backed by DNX Ventures, the Austin-based robotics company is announcing its Series A funding

Diligent Robotics founders

Diligent Robotics founders, Andrea Thomaz (CEO) and Vivian Chu (CTO)

AUSTIN, Texas, March 20, 2020 (GLOBE NEWSWIRE) — Diligent Robotics, the A.I. company building socially intelligent robots for the future of work, announced that it has raised a $10 million series A investment, led by DNX Ventures, and participation from existing investors True Ventures, Ubiquity Ventures and Next Coast Ventures; E14 Fund, Promus Ventures, and Grit Ventures also joined the round.

Their first commercialized product is a hospital robot assistant named Moxi, designed to take some of the busywork off the hands of clinical staff, so they can spend more time focused on patient care.  A landmark report by the Institute of Medicine (https://www.ncbi.nlm.nih.gov/pubmed/25009849) highlights the central role of nursing in patient safety and documents that nurses are increasingly spending more time on non-nursing activities.  Over 30% of hospitals report they cannot find enough candidates to fill open clinical positions, and clinician turnover is at the highest levels at almost 20%. Nursing burnout costs $9B for hospitals annually and $14B for the healthcare system overall. Now more than ever, it is critical for hospitals to find ways to relieve any burdens they can from overworked clinical staff.

Founded in 2017, Diligent Robotics has quickly become the leader in the social robotics sector as the first company to build a robot with social intelligence and mobile manipulation capabilities that helps healthcare staff in their work environments. Last year, Diligent Robotics launched Moxi into the hospital market, and was named one of TIME Magazine’s Best Inventions 2019.  CTO and Co-Founder, Vivian Chu, received MIT Technology Review’s highly prestigious 35 Under 35 for 2019 award, and CEO Andrea Thomaz was named one of Inc Magazine’s 100 Female Founders Building America’s Most Innovative & Ambitious Businesses.

“We envision a future powered by robots that work seamlessly with human teams,” said Dr. Andrea Thomaz, co-founder and chief executive officer of Diligent Robotics.  “We are enabling our hospital customers redesign workflows for their frontline teams, letting nurses make full use of their specialized skills, letting robots handle tedious fetching tasks and other routine work.”

“We build artificial intelligence that enables service robots to collaborate with people and adapt to dynamic human environments,” said Dr. Vivian Chu, co-founder and chief technology officer of Diligent Robotics. “Diligent Robotics is delivering a new class of hospital service robots by building a solution that can autonomously navigate a hospital to perform collaborative tasks with nursing staff.”

The investment from this round will help Diligent Robotics scale their solution to a wider customer base as well as their continued investment in product strategy and development in both hardware and software.

“As the current pandemic and circumstance has shown, the real heroes are our healthcare providers,” said Q Motiwala, partner at DNX Ventures and newly named board member for Diligent Robotics, “Diligent Robotics has built a hospital robot assistant, Moxi, to help solve one of healthcare provider’s biggest challenges: nursing shortages.”

About Diligent Robotics
Diligent Robotics is an Austin-based A.I. company that creates robot assistants that help people with their chores so they can focus on the work they care most about. Moxi is our hospital robot assistant that helps clinical staff with routine, non-patient-facing tasks so they have more time for patient care, and hospitals save money on staff burnout and turnover costs. Moxi has been successfully deployed in several US hospitals and focuses fetch and deliver tasks for frontline clinicians. As a company founded by social robotics experts, we’re proud to be at the forefront of creating robots that incorporate mobile manipulation, social intelligence, and human-guided learning capabilities. We believe that if we can give people the resources that they need to do the work they care most about, we will transform the meaning of “work.” www.diligentrobots.com

About DNX Ventures
DNX Ventures is an early-stage VC firm focusing on B2B Startups that are shaping industries and transforming the way we live and work. Established in 2011, the firm manages multiple funds with AUM about $600 million dollars. We have, across our two existing funds, invested in more than 70 companies with 13 exits, including two IPOs. One of our core value-add services for our portfolio companies is business development support between startups and global conglomerates and we’ve facilitated over 100 signed partnerships so far. Our areas of expertise vary from Enterprise software, Cybersecurity, Frontier Tech, Hardware, Retail tech, to Fintech. https://www.dnx.vc/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f89a358a-0dbd-4011-a379-e708ac07bec6

Media Contact:

Diligent Robotics
Andrea Thomaz
Phone: 617-784-7154 
Email: athomaz@diligentrobots.com

PRA Health Sciences Launches COVID-19 Monitoring Program

RALEIGH, N.C., March 20, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic.

Based on an individual’s COVID-19 disease status, they are assigned to one of three groups:

  • The educational program, which provides vital sign tracking, prevention techniques and mental health support for those who are asymptomatic.
  • The quarantine program, which delivers insights on what to watch for, addresses feelings of fear and isolation, and connects with a healthcare professional for those who have been exposed to COVID-19.
  • The in-depth monitoring program, which addresses symptom management, frequent monitoring by a healthcare professional and care coordination for those who have been diagnosed with COVID-19 and who are still at home.

By downloading the program’s app on their personal mobile devices, participants in the program will be able to report key health metrics related to COVID-19 such as body temperature, heart rate and pulse oximetry. In addition, participants report on symptoms of COVID-19 like shortness of breath, fatigue and changes in coughing. Participants benefit from PRA’s nurse-led clinical call center staff, who monitor the information reported through the app on a daily basis. The trained staff can address physical symptoms, as well as the social and psychological impacts they may be experiencing.

“The COVID-19 pandemic has shown the critical need for organizations of all sizes to be able to remotely assist individuals in monitoring their health and wellbeing,” said Kent Thoelke, Executive Vice President and Chief Scientific Officer at PRA Health Sciences. “Given the scale of the COVID-19 pandemic, we are about to see our healthcare system and its infrastructure significantly stretched. With this program, individuals can have the peace of mind that they can connect with a healthcare professional from the comfort of their own homes while maintaining social distancing. Having the ability to interact with individuals remotely during this uncertain time is critical to maintaining the infrastructure and capability of the healthcare system as well as safety of patients and business continuity.”

The program, which was created by Care Innovations, a PRA Health Sciences company, can be deployed within days. Built on the cloud based Health Harmony Digital Health Platform, the program can also scale immediately and receive updated content as guidelines are changed.

PRA is deploying the COVID-19 Monitoring Program and mobile app to healthcare organizations, large employers, and the company is in discussions with academic institutions, governmental organizations, health departments and other private businesses to roll out the program.

For more information on the COVID-19 Monitoring Program, please contact Care Innovations at https://www.careinnovations.com/contact/ or by phone at 855-885-CARE.


PRA (NASDAQ: PRAH) is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

Laurie Hurst, Director, Communications and Public Relations
HurstLaurie@prahs.com, +1.919.786.8435